ISPIN, INC.

Biotech · Private

Small molecule inhibitors (spinacine) that block HPV E6 protein interactions to restore apoptosis in HPV+ cancer cells

Grants
$241K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel combinatorial approach for treating HPV-associated malignancies$191,115
Federal grantDepartment of Health and Human Services · Phase I · iSPIN iCorp Training$50,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2661Nano Pharmasolutions Inc.—$75K
2662Normunity——
2663UNIVERSAL CELLS, INC.—$60K
2664ISPIN, INC.——
2665Path BioAnalytics, Inc.——
2666Amicus Inc. / DE—$50K
2667Scudo Biosciences Inc—$50K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.